Biora Therapeutics (BIOR) has shared an announcement.
Biora Therapeutics recently revealed promising supplemental data from its Phase 1 trial of BT-600, a pioneering treatment for ulcerative colitis utilizing the NaviCap device to target drug delivery to the colon. The findings show successful systemic absorption of the drug, significantly reduced systemic exposure compared to conventional oral treatments, and effective distribution throughout the colon. The trial highlighted the NaviCap device’s precise release and high tolerability, with no serious adverse events or signs of colon toxicity. This advancement marks a potential breakthrough for targeted ulcerative colitis therapy with sustained drug presence and minimal side effects.
For an in-depth examination of BIOR stock, go to TipRanks’ Stock Analysis page.